BPC-157 (Nasal Spray)

BPC-157 acts via multiple mechanisms: it activates VEGF (angiogenesis), affects FAK-paxillin pathways (cell migration), and modulates the NO and dopaminergic systems. Nasal administration is being investigated as a means of direct central access via the olfactory pathway.

• Investigational stage — no approved nasal formulation exists
• Low molecular weight (~1.4 kDa) theoretically favors nasal absorption
• Research dosing: ~200–500 mcg per application
• No self-compounding instructions are provided

• Nasal administration of BPC-157 is in the investigational stage.
• No approved nasal formulation exists. Data is derived primarily from animal models.
• BPC-157 is a pentadecapeptide (15 amino acids, ~1.4 kDa) — a smaller molecule compared to many peptides, which theoretically favors nasal absorption.

• No approved nasal formulation exists.
• Investigational formulations typically use a concentration of 1 mg/mL in sterile water.
• Self-compounding of a nasal spray is not recommended.

• Refrigerate (2–8°C) after opening.
• Use within 14 days.

• Research dosing: 200–500 mcg per nostril.
• Frequency: 2–3 times daily.

• Refrigerate (2–8°C).
• Protect from light.

• Not approved by the FDA or EMA in any form.
• Data on nasal administration is derived primarily from animal models.
• The subcutaneous form remains the most studied route of administration.
• No self-compounding instructions are provided.

Potential Benefits

• Theoretical central neuroprotection (animal data)
• Non-invasive administration
• Low molecular weight favors nasal absorption

Potential Side Effects

• Mild nasal irritation (possible)
• Insufficient safety data for the nasal form in humans
• Theoretical risk: VEGF activation (angiogenesis)

1. BPC-157 Neuroprotective Action — A Review — A review of the neuroprotective properties of BPC-157 in animal models.
   Source →
2. BPC-157 and the Blood-Brain Barrier — Data on the crossing of BPC-157 through the blood-brain barrier.
   Source →